Please select the eligibility criteria that correspond to the clinical trial below.
Title: Double-blind Study to Assess the Impact of Normalization of Hemoglobin Compared to Partial Correction of Hemoglobin With EPREX�/ERYPO� on Left Ventricular Structure in Early Hemodialysis Patients (RWJ-22512)
Brief Summary: The purpose of this study in early hemodialysis patients (on dialysis 3 to 18 months) is to assess the effect of correction versus partial correction of anemia using epoetin alfa on heart pumping function.


Options:
A: Inclusion Criteria:

Participants diagnosed with ESKD and undergoing haemodialysis for ≥ 3 months, aged 18 years and above, able to speak and understand Nepali language and willing to participate will be included in this study.

Exclusion Criteria:

Participants who are in the early stage of CKD or not dependent on HD, those acutely ill, diagnosed with cognitive impairment and those who are not willing to participate will be excluded.
B: Inclusion Criteria:

* Maintenance hemodialysis for ≥3 or months
* Adequately dialyzed (Kt/V ≥1.2 measured within last 3 months)
* Expected to remain in present hemodialysis shift for next 4 months
* Expected to remain on hemodialysis for at least 6 months
* 18 years or older

Exclusion Criteria:

* Acute or chronic medical conditions that would make intra-dialysis yoga potentially hazardous
* Unstable cardiac disease e.g. angina, life threatening arrhythmia
* Chronic lung disease that prevents gentle exercise or deep breathing exercises
* Active cerebrovascular disease
* Major depression
* Chronic symptoms of nausea, vomiting, or diarrhea
* Current participation in exercise or mind body program/practice
* Cognitive impairment (MME ≤ 24) measured at baseline testing visit
C: Inclusion Criteria:

* age greater than 18 years
* undergoing hemodialysis for 3 months or more or healthy control without kidney disease

Exclusion Criteria:

* inability to give informed consent
* diagnosis of diabetes mellitus
* musculoskeletal contraindication to exercise
* infection requiring intravenous antibiotics within 2 months
* hospitalization within 2 months
* ingestion of antioxidant supplements within one month
* requirement for systemic anticoagulation
* estimated GFR \<60 ml/min/1.73 m2 for healthy controls
D: Inclusion Criteria:

* On hemodialysis for 3 to 18 months and expected to remain on hemodialysis for at least two more years and with a life expectancy of a year or more
* Kidney transplant patients, whose transplant has failed, and now have been on hemodialysis for 3-18 months, may be eligible for the study, if they are not receiving excessive immunosuppression (e.g., \<=10 mg of steroids/day allowed)
* Pre-dialysis hemoglobin 8-12 g/dL, inclusive, within the previous month (single reading is sufficient)
* Stable hemodialysis vascular access, within the previous 3 months
* No heart disease or asymptomatic heart disease without enlarged heart

Exclusion Criteria:

* Heart diseases for which surgical intervention occurred during the previous two years or which may require intervention within the next year
* Patients with medical conditions likely to affect the response to epoetin
* Predialysis sitting diastolic blood pressure \>= 100 mmHg on average for the previous month
* Folate, Vitamin B12, or transferrin deficiency
* History of seizure within 1 year
* Transfusion within 30 days prior to study entry.

Answer: D